{"id":5684,"date":"2010-12-24T11:55:26","date_gmt":"2010-12-24T16:55:26","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=5684"},"modified":"2011-07-19T17:45:20","modified_gmt":"2011-07-19T21:45:20","slug":"looking-back-at-2010","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/12\/24\/looking-back-at-2010\/","title":{"rendered":"A Look Back at 2010"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
CardioExchange invited a wide range of members\u2212researchers, teachers, private practice clinicians, and fellows\u2212to give us their impressions of the most important developments in cardiology in 2010. We summarize their lists here and offer a running scorecard. Click the authors’ names to read the full posts.\u00a0 The same CardioExchange members offered predictions for 2011, and you can see a summary of those here<\/a>.<\/em> Also, for comparison, check out the AHA list of the top 10 advances in cardiovascular research this year<\/a>.<\/em><\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
What would your choices have been? Any sins of inclusion or exclusion here in your opinion? Join the conversations.<\/strong><\/p>\n


\n<\/strong><\/td>\n<\/tr>\n

\n
\n<\/td>\n<\/tr>\n
\"\"<\/a>Steven E Nissen, MD<\/strong><\/a>
\n1. Rosiglitazone withdrawal in Europe and restriction in the U.S.
\n2. Approval of dabigatran
\n3. ACCORD lipid study<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>JoAnne M. Foody, MD<\/strong><\/a>
\n1. ACCORD Lipid
\n2. ACCORD BP
\n3. Meta-analysis of statins in high-risk primary prevention and all-cause mortality.<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Roger Blumenthal, MD <\/strong><\/a>
\n1. Approval of dabigatran
\n2. JUPITER\/Meta-analysis of women from prevention trials study of women with high CRP or dyslipidemia
\n3. ACCORD BP and ACCORD Lipids<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"\"\"Richard A. Lange, MD, MBA and L. David Hillis, MD<\/strong><\/a>
\n1. CREST trial (Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis)
\n2. PARTNER trial (Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery)
\n3. COGENT trial (Clopidogrel with or without Omeprazole in Coronary Artery Disease).<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Deepak L. Bhatt, MD, MPH<\/strong><\/a>
\n1. PARTNER trial (Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery)
\n2. RAFT (Resynchronization\u2013Defibrillation for Ambulatory Heart Failure Trial)
\n3. DEFINE trial (Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib)<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>John Brush, MD<\/strong><\/a>
\n1. PARTNER trial (Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery)
\n2. The Symplicity HTN-2 trial
\n3. DEFINE trial (Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib)<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>John Mandrola, MD<\/strong><\/a>
\n1. Approval of dabigatran
\n2. Mark Midei story (Maryland doctor accused of implanting hundreds of unnecessary stents)
\n3. Percutaneous therapy for valvular heart disease (most notably the PARTNER trial)<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Thad F Waites, MD<\/strong><\/a>
\n1. Approval of dabigratran
\n2. Passage of the Patient Protection and Affordable Care Act
\n3. Mark Midei story (Maryland doctor accused of implanting hundreds of unnecessary stents)<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Barry M. Massie, MD<\/strong> <\/strong><\/a>
\n1. Aldosterone antagonists continue their winning streak (RALES, EPHESUS, and EMPHASIS)
\n2. Migrating cardiac resynchronization therapy (CRT) into milder heart failure (RAFT)
\n3. Disappointing data on remote monitoring to improve heart-failure outcomes (Tele-HF and TIM-HF)<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>John Ryan, MD<\/strong><\/a>
\n1. Study on effects of CYP2C19 genotype on outcomes of clopidogrel treatment
\n2. PARTNER study (Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery)
\n3. Studies showing risk of low-dose ionizing radiation from medical imaging procedures<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>James De Lemos, MD<\/strong><\/a>
\n1. ACGME releases new duty hour rules
\n2. Aldosterone antagonists continue their winning streak with publication of EMPHASIS-HF
\n3. The merging of cardiology practices and hospitals.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
*** Vote Tally ***<\/strong><\/td>\n<\/tr>\n
<\/td>\n<\/tr>\n
VOTES <\/strong><\/td>\n TOPIC<\/strong><\/td>\n<\/tr>\n
5<\/td>\nPARTNER trial<\/td>\n<\/tr>\n
4<\/td>\nDabigatran approval<\/td>\n<\/tr>\n
3<\/td>\nACCORD Lipid<\/td>\n<\/tr>\n
2<\/td>\nACCORD BP<\/td>\n<\/tr>\n
2<\/td>\nRAFT trial<\/td>\n<\/tr>\n
2<\/td>\nRisk related to low-dose ionizing radiation from medical imaging<\/td>\n<\/tr>\n
2<\/td>\nMark Midei story (doctor accused of implanting unnecessary stents)<\/td>\n<\/tr>\n
2<\/td>\nAldosterone\/EMPHASIS trial<\/td>\n<\/tr>\n
1<\/td>\nJUPITER substudy in women<\/td>\n<\/tr>\n
1<\/td>\nMeta-analysis of statins for high-risk primary prevention in women<\/td>\n<\/tr>\n
1<\/td>\nCYP2C19 genotype\/clopidogrel resistance study<\/td>\n<\/tr>\n
1<\/td>\nDEFINE trial<\/td>\n<\/tr>\n
1<\/td>\nRosiglitazone restrictions<\/td>\n<\/tr>\n
1<\/td>\nHealthcare reform<\/td>\n<\/tr>\n
1<\/td>\nRemote monitoring of HF patients (Tele-HF and TIM-HF)<\/td>\n<\/tr>\n
1<\/td>\nStudy on effects of CYP2C19 genotype on outcomes of clopidogrel treatment<\/td>\n<\/tr>\n
1<\/td>\nNew ACGME duty hour rules<\/td>\n<\/tr>\n
1<\/td>\nMerging of cardiology practices and hospitals<\/td>\n<\/tr>\n
1<\/td>\nCOGENT trial<\/td>\n<\/tr>\n
1<\/td>\nCREST trial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

CardioExchange invited a wide range of members\u2212researchers, teachers, private practice clinicians, and fellows\u2212to give us their impressions of the most important developments in cardiology in 2010. We summarize their lists here and offer a running scorecard. Click the authors’ names to read the full posts.\u00a0 The same CardioExchange members offered predictions for 2011, and you […]<\/p>\n","protected":false},"author":343,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[634],"class_list":["post-5684","post","type-post","status-publish","format-standard","hentry","category-general","tag-2010-review"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/343"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=5684"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5684\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=5684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=5684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=5684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}